The Effect of Psychoeducation Focused on Reducing Internalized Stigma

NCT06347848 | Not Yet Recruiting

• 1 other identifier: IstanbulUCKA
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

In the fight against stigma, the focus should be on the education of individuals diagnosed with mental illness. Psychoeducation has an important place in the treatment and rehabilitation of mental health problems. Psychoeducation is necessary for early recognition of signs and symptoms of diseases, ensuring compliance with treatment, improving coping skills, as well as combating stigma, preventing internalized stigma, and counteracting social stigma. If individuals with mental disorders have adequate knowledge about the causes of stigma, they may be less prone to internalized stigma.

Conditions

Schizophrenia; Treatment Adherence; Stigma, Social

Keywords

Schizophrenia; Treatment Adherence; Internalized Stigma; Psychoeducation

Outcome Measures

Primary Outcomes (2)

• Internalized Stigma of Mental Illness Scale

  It is a self-report scale consisting of 29 items and assessing internal stigma. The scale includes: 1. Alienation (6 items), 2. Endorsement of Stereotypes (7 items), 3. Perceived Discrimination (5 items), 4. Social Withdrawal (6 items) and 5. Resistance to Stigma (5 items). It has five subscales. The items in the scale are on a four-point Likert-type scale as "I strongly disagree" (1 point), "I disagree" (2 points), "I agree" (3 points), "I strongly agree" (4 points). is answered. Items of the "Resistance to stigma" subscale are scored reversely. The total score obtained by summing the scores of the five subscales varies between 29 and 116 points. Higher scores from the scale mean that the person's internalized stigma is more severe in a negative way. While the internal consistency coefficient obtained for the entire scale was found to be 0.93, the split-half reliability of the scale was determined as 0.89.

  4 Month

• Medication Adherence Reporting Scale

  It is a 5-point Likert type scale consisting of 5 questions. The scale is used to evaluate medication compliance in many diseases such as blood pressure, diabetes, rheumatoid arthritis, inflammatory bowel disease, hyperlipidemia, chronic pain, and bipolar mood disorder. The total test score is obtained by adding the scores obtained from the items. Scores from the scale vary between 5 and 25. An increase in the scores obtained indicates compatibility, and a decrease in the scores indicates non-compliance. It was found that the scale was evaluated with a single factor structure and had good levels of criterion and discriminant validity and reliability (Cronbach Alpha = 0.85).

  4 Month

Study Arms (2)

Experimental

EXPERIMENTAL

Psyhcoeducation Group (Experimental) Psychoeducation focused on reducing internalized stigma will be applied to the experimental group.

Other: Psychoeducation Focused on Reducing Internalized Stigma

No Intervention

NO INTERVENTION

Controls (Control Group) No intervention will be applied to the control group.

Interventions

Psychoeducation Focused on Reducing Internalized Stigma OTHER

Participants will be randomized and divided into experimental and control groups. Initial measurements will be collected through a face-to-face meeting. While the control group will continue to receive routine Community Mental Health Center service, the experimental group will receive a psychoeducation program focused on reducing internalized stigma in addition to the routine Community Mental Health Center service. After the program is completed, final measurements of the experimental and control groups will be collected. The program is planned to consist of 7 sessions, once a week, and approximately 60-90 minutes are expected to be allocated for each session. Sessions will be divided into two sessions: a 30-40 minute session and a 15 minute break.

Experimental

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Volunteer to participate in the research,
• Diagnosed with schizophrenia according to DSM-V TR diagnostic criteria,
• Over 18 years old,
• Being in remission for 2 months,
• At least primary school graduate,
• Residing in Edirne city center and its districts,
• Individuals without hearing or understanding problems.

You may not qualify if:

• Having a diagnosis of dementia or other organic mental disorder as an additional diagnosis,
• Individuals with a history of substance abuse (other than nicotine).

Sponsors & Collaborators

• Istanbul University - Cerrahpasa: lead

Study Sites (1)

Istanbul University - Cerrahpasa (IUC)

Istanbul, Şişli, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Schizophrenia; Treatment Adherence and Compliance; Social Stigma

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic Disorders; Mental Disorders; Health Behavior; Behavior; Social Behavior

Study Officials

• Ozge SUKUT, PhD

  Istanbul University - Cerrahpasa

  STUDY DIRECTOR

Central Study Contacts

Kadriye ATAR, MSc

CONTACT

5065595119; kadriye.atar@ogr.iuc.edu.tr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Two parallel groups randomized control study

Study Record Dates

• First Submitted: March 30, 2024
• First Posted: April 4, 2024
• Study Start: April 30, 2024
• Primary Completion: May 1, 2024
• Study Completion: September 1, 2024
• Last Updated: April 4, 2024

Record last verified: 2024-03

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)